BriLife
id:
brilife-219-778468
title:
BriLife
text:
BriLife, also known as IIBR-100, is a replication-competent recombinant VSV viral vectored COVID-19 vaccine candidate. It was developed by the Israel Institute for Biological Research (IIBR). The IIBR partnered with the US-based NRx Pharmaceuticals to complete clinical trials and commercialize the vaccine. A study conducted in hamsters suggested that one dose of the vaccine was safe and effective at protecting against COVID-19.
brand slug:
wiki
category slug:
encyclopedia
description:
Vaccine candidate against COVID-19
original url:
https://en.wikipedia.org/wiki/BriLife
date created:
2021-04-01T06:51:45Z
date modified:
2024-09-13T10:49:43Z
main entity:
{"identifier":"Q100694835","url":"https://www.wikidata.org/entity/Q100694835"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/3/39/Reuven_Rivlin_with_the_first_vaccinator_in_Phase_B_of_the_Israeli_Vaccine_of_the_Israeli_Biological_Institute%2C_January_2021_%28GPOABG_4084%29.jpg","width":1615,"height":1706}
fields total:
13
integrity:
16